Annual Accounts Payable
$14.93 M
+$3.68 M+32.71%
December 31, 2023
Summary
- As of February 7, 2025, ZNTL annual accounts payable is $14.93 million, with the most recent change of +$3.68 million (+32.71%) on December 31, 2023.
- During the last 3 years, ZNTL annual accounts payable has risen by +$6.26 million (+72.34%).
- ZNTL annual accounts payable is now at all-time high.
Performance
ZNTL Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$8.20 M
-$12.24 M-59.87%
September 30, 2024
Summary
- As of February 7, 2025, ZNTL quarterly accounts payable is $8.20 million, with the most recent change of -$12.24 million (-59.87%) on September 30, 2024.
- Over the past year, ZNTL quarterly accounts payable has dropped by -$6.06 million (-42.50%).
- ZNTL quarterly accounts payable is now -59.87% below its all-time high of $20.44 million, reached on June 30, 2024.
Performance
ZNTL Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
ZNTL Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +32.7% | -42.5% |
| 3 y3 years | +72.3% | -42.5% |
| 5 y5 years | +335.0% | -42.5% |
ZNTL Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +32.7% | -59.9% | at low |
| 5 y | 5-year | at high | +248.0% | -59.9% | +94.5% |
| alltime | all time | at high | +335.0% | -59.9% | +94.5% |
Zentalis Pharmaceuticals Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $8.20 M(-59.9%) |
| Jun 2024 | - | $20.44 M(+94.6%) |
| Mar 2024 | - | $10.50 M(-29.6%) |
| Dec 2023 | $14.93 M(+32.7%) | $14.93 M(+4.6%) |
| Sep 2023 | - | $14.26 M(+15.9%) |
| Jun 2023 | - | $12.30 M(-4.0%) |
| Mar 2023 | - | $12.82 M(+14.0%) |
| Dec 2022 | $11.25 M | $11.25 M(+14.5%) |
| Sep 2022 | - | $9.82 M(-18.4%) |
| Jun 2022 | - | $12.04 M(-8.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $13.16 M(+13.6%) |
| Dec 2021 | $11.59 M(+33.8%) | $11.59 M(+44.0%) |
| Sep 2021 | - | $8.05 M(-2.7%) |
| Jun 2021 | - | $8.27 M(-0.8%) |
| Mar 2021 | - | $8.34 M(-3.7%) |
| Dec 2020 | $8.66 M(+101.9%) | $8.66 M(+59.3%) |
| Sep 2020 | - | $5.44 M(+28.9%) |
| Jun 2020 | - | $4.22 M(-39.9%) |
| Mar 2020 | - | $7.02 M(+63.7%) |
| Dec 2019 | $4.29 M(+25.0%) | $4.29 M |
| Dec 2018 | $3.43 M | - |
FAQ
- What is Zentalis Pharmaceuticals annual accounts payable?
- What is the all time high annual accounts payable for Zentalis Pharmaceuticals?
- What is Zentalis Pharmaceuticals annual accounts payable year-on-year change?
- What is Zentalis Pharmaceuticals quarterly accounts payable?
- What is the all time high quarterly accounts payable for Zentalis Pharmaceuticals?
- What is Zentalis Pharmaceuticals quarterly accounts payable year-on-year change?
What is Zentalis Pharmaceuticals annual accounts payable?
The current annual accounts payable of ZNTL is $14.93 M
What is the all time high annual accounts payable for Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals all-time high annual accounts payable is $14.93 M
What is Zentalis Pharmaceuticals annual accounts payable year-on-year change?
Over the past year, ZNTL annual accounts payable has changed by +$3.68 M (+32.71%)
What is Zentalis Pharmaceuticals quarterly accounts payable?
The current quarterly accounts payable of ZNTL is $8.20 M
What is the all time high quarterly accounts payable for Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals all-time high quarterly accounts payable is $20.44 M
What is Zentalis Pharmaceuticals quarterly accounts payable year-on-year change?
Over the past year, ZNTL quarterly accounts payable has changed by -$6.06 M (-42.50%)